The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Precision Promise: pamrevlumab with chemotherapy in pancreatic cancer
Vincent Picozzi, MD, Virginia Mason Medical Center, Seattle, WA, explains how the Precision Promise trial (NCT04229004) represents a dual innovation in pancreatic cancer research – evaluating pamrevlumab as a treatment while also introducing a novel trial design with advanced statistical analyses. This adaptive platform trial explored the efficacy of pamrevlumab in combination with gemcitabine and nab-paclitaxel in both first- and second-line treatment settings. Despite a negative trial outcome, the study continues to offer valuable insights into future trial methodologies and treatment strategies for pancreatic cancer. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
